Organon & Co (OGN) shares plummeted 24.48% in pre-market trading on Thursday following the release of its first-quarter 2025 financial results. The pharmaceutical company reported disappointing earnings and revenue figures, alongside a significant cut to its quarterly dividend.
For the first quarter ended March 31, Organon reported net income of $87 million, down from $201 million in the same period last year. Revenue fell 6.7% to $1.51 billion, while adjusted earnings per share (EPS) came in at $1.02, lower than the $1.22 reported a year ago. Despite beating analyst expectations, the year-over-year decline in performance has sparked investor concerns.
Adding to the negative sentiment, Organon announced a drastic reduction in its quarterly dividend from $0.28 to $0.02 per share. CEO Kevin Ali explained that this decision was made to reset capital-allocation priorities and accelerate progress toward deleveraging. The company is now focusing on achieving a net leverage ratio below 4.0x by year-end. While Organon reaffirmed its full-year revenue and Adjusted EBITDA margin guidance, the dividend cut and weaker quarterly results have clearly shaken investor confidence, leading to the significant stock price decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.